Iterum Therapeutics Presented a Scientific Poster at ECCMID 2025 Highlighting the Impact of Age on Antibiotic Resistance and Efficacy of Antibiotics

Company Overview - Iterum Therapeutics plc focuses on developing next-generation oral and IV antibiotics to combat multi-drug resistant pathogens in both community and hospital settings [1][2] - The company is advancing its first compound, sulopenem, which has shown potent in vitro activity against various resistant bacteria [2] - Iterum has received FDA approval for ORLYNVAH™ (oral sulopenem) for treating uncomplicated urinary tract infections (uUTI) in adult women with limited or no alternative treatment options [2] Recent Developments - A poster titled "Impact of age on antibiotic resistance and efficacy of antibiotics for women with uncomplicated urinary tract infection (uUTI)" was presented at the 35th Annual European Congress of Clinical Microbiology and Infectious Disease (ECCMID) [1] - The poster was presented by Dr. Sailaja Puttagunta on April 13, 2025, and will be available on the company's website [1] Product Information - ORLYNVAH™ is a novel oral penem antibiotic specifically designed for treating uUTI, demonstrating strong activity against Enterobacterales species that are resistant to third-generation cephalosporins [3]